Cargando…

Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients

BACKGROUND: The objective of the study was to describe the healthcare resource utilization (HCRU) and associated costs with hospitalized patients receiving specific versus non-specific oral anticoagulation reversal therapy for life-threatening bleeds and emergency surgeries or urgent procedures. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spyropoulos, Alex C., Hartaigh, Briain O., Cao, Zhun, Lipkin, Craig, Robinson, Scott B., Caberwal, Harjeet, Petrini, Michaela, Wang, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827241/ https://www.ncbi.nlm.nih.gov/pubmed/35211221 http://dx.doi.org/10.14740/cr1307

Ejemplares similares

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis
por: Shin, Dong Geum, et al.
Publicado: (2015)

Impact of age on thromboembolic events in patients with non‐valvular atrial fibrillation
por: Kim, Yun Gi, et al.
Publicado: (2019)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
por: Lin, Yu-Sheng, et al.
Publicado: (2021)

Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation
por: Arya, Arash
Publicado: (2013)

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
por: Wu, Jia, et al.
Publicado: (2020)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
por: Di Biase, Luigi
Publicado: (2016)

Use of Anticoagulants in Patients With Non-Valvular Atrial Fibrillation Who Are at Risk of Falls
por: Shanah, Layla, et al.
Publicado: (2020)

Factors Associated with Anticoagulation Adherence in Chinese Patients with Non-Valvular Atrial Fibrillation
por: Song, Ting, et al.
Publicado: (2021)

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism
por: Han, Donghee, et al.
Publicado: (2016)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project
por: Xiong, Qinmei, et al.
Publicado: (2016)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Tailored Anticoagulation for Thromboembolic Risk Reduction in Paroxysmal Atrial Fibrillation
por: Matos, Jason D., et al.
Publicado: (2018)

Erratum to: The Global Anticoagulant Registry in the FIELD – Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

ANMCO position paper ‘Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation’
por: Mocini, David, et al.
Publicado: (2022)

Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non‐valvular atrial fibrillation (cognitive decline and dementia in patients with non‐valvular atrial fibrillation [CAF] trial)
por: Bunch, Thomas Jared, et al.
Publicado: (2022)

Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
por: Halperin, Jonathan L, et al.
Publicado: (2014)

Psychological effects of treatment with novel oral anticoagulants in non-valvular atrial fibrillation patients
por: Öncel, Can Ramazan
Publicado: (2016)

Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation
por: Kuo, Liang-Tseng, et al.
Publicado: (2021)

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021)

Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
por: Hwang, Ki Won, et al.
Publicado: (2023)

Management and Anticoagulation Treatment of Non-Valvular Atrial Fibrillation in Elderly Patients: The Dali Study
por: Huang, Hong, et al.
Publicado: (2023)

Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia
por: Alosaimi, Hind M., et al.
Publicado: (2022)

Characteristics of patients with venous thromboembolism and atrial fibrillation in Venezuela
por: Bennett, Dimitri, et al.
Publicado: (2011)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

Serial changes in the trends of direct oral anticoagulant use and incidence of thromboembolisms and major bleeding events in very old patients with non-valvular atrial fibrillation
por: Takahashi, Masahiko, et al.
Publicado: (2023)

Editorial to “The differences of atrial thrombus locations and variable response to anticoagulation in non‐valvular atrial fibrillation with ventricular cardiomyopathy”
por: Chung, Wei‐Hsin, et al.
Publicado: (2020)

Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients
por: Umei, Masahiko, et al.
Publicado: (2017)

Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure
por: Amin, Alpesh, et al.
Publicado: (2019)

Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
por: Generalova, Daria, et al.
Publicado: (2020)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5avlj0rvfrsi15i547cn3aq01h